Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Serena Williams says she has lost weight using GLP-1 medication. The drugs help manage blood sugar and promote weight loss, ...

The 23-time Grand Slam champion says the medication is no shortcut, but a tool alongside exercise, diet and discipline ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and ...

Given the potential side effects of GLP-1 prescription drugs, many Utahns are seeking alternative methods to naturally boost ...

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are also called GLP-1 medications, short for glucagon-like peptide-1 agonists, ...

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...